

---

## Appendix S1

### Search strategy (June 7<sup>th</sup>, 2021):

Select a database: Web of Science Core Collection

Document types: Article

Language: English

Duration: 2010.1-2020.12

Citation Indexes: The Science Citation Index Expanded (SCI-EXPANDED),

the Social Sciences Citation Index (SSCI),

the Conference Proceedings Citation Index-Science (CPCI-S),

the Conference Proceedings Citation Index-Social Science & Humanities (CPCI-SSH), the Book Citation Index-Science (BKCI-S),

the Index Chemicus (IC)

Results: 4263

Boolean operation rules:

```
((TS= ("rectum cancer") OR ("Rectal Cancers") OR ("Neoplasm, Rectal") OR ("Rectal Neoplasm") OR ("Rectum Neoplasms") OR ("Neoplasm, Rectum") OR ("Rectum Neoplasm") OR ("Rectal Tumors") OR ("Rectal Tumor") OR ("Tumor, Rectal") OR ("Neoplasms, Rectal") OR ("Cancer of Rectum") OR ("Rectum Cancers") OR ("Rectum Cancers") OR ("Rectal Cancer") OR ("Rectum Cancer") OR ("Cancer, Rectum") OR ("Cancer of the Rectum") OR ("Cancer, Rectal")) AND ((TS= ("radiation oncology") OR ("radiation therapy") OR (radiotherapy) OR ("conformal radiation therapy") OR ("conformal radiotherapy") OR ("external beam radiation therapy") OR ("external beam radiotherapy") OR (EBRT) OR ("intensity-modulated radiation therapy") OR ("intensity modulated radiation therapy") OR ("intensity-modulated radiotherapy") OR ("intensity modulated radiotherapy") OR (IMRT) OR ("stereotacticbody radiotherapy") OR ("neo-adjuvant chemoradiation") OR ("neoadjuvant chemoradiation") OR ("adjuvant chemoradiation") OR ("stereotacticbody radiation therapy") OR (SBRT) OR ("stereotactic radiosurgery") OR ("stereotactic radiotherapy") OR ("stereotactic radiation therapy") OR ("Image Guided Radiotherapy") OR ("Image Guided Radiation therapy") OR (IGRT) OR ("image guided adaptive radiotherapy") OR ("image guided adaptive radiation therapy") OR ("adaptive radiation therapy") OR ("adaptive radiotherapy") OR (IGART) OR (VMAT) OR ("Volumetric Intensity Modulated Arc Therapy") OR ("proton radiotherapy") OR ("proton radiation therapy")) NOT (TS= ("Radioisotope Brachytherapy") OR ("Curiotherapy") OR ("Interstitial Radiotherapy") OR ("Implant Radiotherapy") OR ("high dose rate") OR (HDR) OR ("low dose rate") OR (LDR) OR ("pulsed dose rate") OR (PDR) OR ("medium dose rate") OR (MDR) OR (brachytherapy))))))
```

## Appendix S2

### Supplementary Tables:

**Table S 1.** Top 10 countries based on count.

**Table S 2.** Top 10 institutes based on count.

**Table S 3.** Top 10 most productive journals.

**Table S 4.** Top 10 journals with most co-citation count.

**Table S 5.** Details of the 17 clusters.

**Table S 6.** The representative papers of Cluster 1.

**Table S 7.** The representative papers of Cluster 7.

**Table S 8.** The representative papers of Cluster 8.

**Table S 9.** The representative papers of Cluster 17.

**Table S 10.** Top103 References with the Strongest Citation Bursts.

**Table S 1.** Top 10 countries based on count.

Rank	Count	Centrality	Country
1	888	0	USA
2	590	0.07	PEOPLES R CHINA
3	387	0	NETHERLANDS
4	353	0	SOUTH KOREA
5	339	0	ITALY
6	294	0	JAPAN
7	292	0.35	ENGLAND
8	268	0	GERMANY
9	213	0	FRANCE
10	179	0.15	SPAIN

**Table S 2.** Top 10 institutes based on count.

Rank	Count	Centrality	Institutes
1	114	0.06	LEIDEN UNIVERSITY
2	96	0.09	MAASTRICHT UNIVERSITY
3	95	0.00	FUDAN UNIVERSITY
4	94	0.03	MEMORIAL
			SLOAN-KETTERING
5	92	0.32	CANCER CENTER
			UNIVERSITY TEXAS MD
6	86	0.25	ANDERSON CANCER
			CENTER
7	83	0.03	NATIONAL CANCER
8	71	0.28	CENTER
9	69	0.11	SUN YAT-SEN UNIVERSITY
10	69	0.03	CATHARINA HOSPITAL
			KAROLINSKA INSTITUTION
			YONSEI UNIVERSITY

**Table S 3.** Top 10 most productive journals

Rank	Journals	Count	% of 4,263	IF ( 2020 )
1	DISEASES OF THE COLON RECTUM	195	4.575	3.99
2	COLORECTAL DISEASE	183	4.293	2.765
3	INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY	156	3.660	5.856

PHYSICS				
4	INTERNATIONAL JOURNAL OF COLORECTAL DISEASE	132	3.097	2.108
5	RADIOTHERAPY AND ONCOLOGY	124	2.909	4.855
6	ANNALS OF SURGICAL ONCOLOGY	123	2.886	4.0608
7	EJSO	99	2.323	3.956
8	RADIATION ONCOLOGY	99	2.323	2.817
9	BMC CANCER	81	1.901	3.15
10	ONCOTARGET	69	1.619	-

**Table S 4.** Top 10 journals with most co-citation count.

Ran k	Cou nt	Centrality	Cited Journals	IF
1	277 5	0.77	JOURNAL OF CLINICAL ONCOLOGY	32.9557
2	227 7	0.65	DISEASES OF THE COLON RECTUM	3.9909
3	219 6	0.95	NEW ENGLAND JOURNAL OF MEDICINE	
4	214 0	0.6	INTERNATIONAL JOURNAL OF RADIATION	33.7515
5	211 0	0.27	ANNALS OF SURGERY	10.1296
6	182 7	0	ANNALS OF SURGICAL ONCOLOGY	4.0608
7	182 5	0.08	BRITISH JOURNAL OF SURGERY	74.6982
8	166 5	0.04	LANCET ONCOLOGY	5.8593
9	143 9	0.04	LANCET	5.6759
10	142 3	0.04	COLORECTAL DISEASE	2.7688

**Table S 5.** Details of the 17 clusters. ( cluster summary of clusters )

Cluster ID	Size	Silhouett e	Mean( Year )	Label (LLR)(4-5 ↑)
0	34	0.947	2009	conjoint analysis (9.31, 0.005); late effects (9.31, 0.005); randomized trials (6.28, 0.05); delineation atlas (4.65, 0.05)
1	29	1	2015	organ preservation (13.29, 0.001); radiomics (13.29, 0.001); watch and wait (13.12, 0.001); magnetic resonance imaging (10.11, 0.005)

2	25	0.979	2008	f-18-fdg parametric image (6.79, 0.01); dual-time f-18-fdg pet (6.79, 0.01); gross target volume (6.79, 0.01); diffusion-weighted mri (6.79, 0.01);
3	25	0.909	2006	preoperative chemoradiotherapy (6.92, 0.01); capecitabine (5.59, 0.05); tumour regression (5.22, 0.05); zap70 (5.22, 0.05)
4	24	0.875	2008	adjuvant chemotherapy (11.36, 0.001); adenocarcinoma (6.37, 0.05); delphi method (5.84, 0.05); near-complete (5.84, 0.05)
5	22	0.921	2010	prognosis (9.98, 0.005); elderly (5.14, 0.05); immunotherapy (5.14, 0.05); anal canal (4.36, 0.05)
6	21	1	2006	capecitabine (10.88, 0.001); cetuximab (5.76, 0.05); anal cancer (5.33, 0.05); radiation (5.04, 0.05); sphincter preservation (4.74, 0.05) interval (21.98, 1.0E-4); short-course radiotherapy (13.16, 0.001);
7	16	0.984	2014	texture analysis (13.16, 0.001); mucinous adenocarcinoma (8.76, 0.005)
8	15	0.962	2013	adjuvant chemotherapy (10.91, 0.001); circumferential resection margin (9.3, 0.005); MRI (5.86, 0.05); pathologic complete response (6.18, 0.05)
9	13	0.911	2010	local excision (20.85, 1.0E-4); watch and wait (10.43, 0.005); rectum-preserving approach (7.8, 0.01); lymphoscintigraphy (7.8, 0.01); tem surgery (7.8, 0.01)
10	11	1	2006	leucovorin (7.45, 0.01); post-treatment rectal cancer (6.4, 0.05); minimally invasive approach (6.4, 0.05); resection margins (6.4, 0.05)
11	9	1	2011	laparoscopic surgery (18.89, 1.0E-4); laparoscopy (15.94, 1.0E-4); oncological outcomes (12.57, 0.001); robotic surgical procedures (12.57, 0.001)
12	7	0.979	2005	adjuvant radiotherapy (10.63, 0.005); disparities (8.6, 0.005); helical tomotherapy (8.6, 0.005); simultaneous integrated boost (8.6, 0.005)
13	6	1	2006	planning target volume (7.28, 0.01); tktl1 (7.28, 0.01); hypoxia (7.28, 0.01); rectal motion (7.28, 0.01)
14	5	0.991	2005	predictive and prognostic factor (8.37, 0.005); bispecific antibody (8.37, 0.005); histologic regression (8.37, 0.005); response evaluation (8.37, 0.005)
15	5	0.986	2010	functional result (7.55, 0.01); second mitochondria-derived activator of caspase vascular endothelial growth factor (7.55, 0.01); colorectal adenocarcinoma (7.55, 0.01); helical (7.55, 0.01)
17	3	0.978	2014	chemoembolization (7.11, 0.01); clinical study (7.11, 0.01); neoadjuvant chemoradiotherapy (6.07, 0.05); locally-advanced rectal cancer (4.4, 0.05)

**Table S 6.** The representative papers of Cluster 1.

Serial Number	Title
---------------	-------

---

1	Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer
2	Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control
3	High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study
4	Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management?
5	Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer

---

**Table S 7.** The representative papers of Cluster 7.

Serial Number	Title
1	Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial
2	Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6)
3	Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer
4	Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial
5	Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial

---

**Table S 8.** The representative papers of Cluster 8.

Serial Number	Title
1	Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study
2	Tumour ADC measurements in rectal cancer: effect of ROI methods on ADC values and interobserver variability
3	Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study
4	Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data
5	Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study

---

**Table S 9.** The representative papers of Cluster 17.

Serial Number	Title
---------------	-------

---

- 1 Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial
- 2 Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04
- 3 Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial

**Table S 10.** Top103 References with the Strongest Citation Bursts.

Rank	References	Year	Strength	Begin	End	2010 - 2020
1	<a href="#">Birgisson H, 2005, J CLIN ONCOL, V23, P8697, DOI</a>	2005	9.7303	2010	2011	
2	<a href="#">Vecchio FM, 2005, INT J RADIAT ONCOL, V62, P752, DOI</a>	2005	16.0515	2010	2013	
3	<a href="#">Brown G, 2006, BRIT MED J, V333, P779, DOI</a>	2006	15.4385	2010	2014	
4	<a href="#">Nagtegaal ID, 2008, J CLIN ONCOL, V26, P303, DOI</a>	2008	9.0443	2010	2014	
5	<a href="#">Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI</a>	2004	6.8796	2010	2012	
6	<a href="#">Peeters KCMJ, 2005, J CLIN ONCOL, V23, P6199, DOI</a>	2005	21.0731	2010	2012	
7	<a href="#">Habr-Gama A, 2004, ANN SURG, V240, P711, DOI</a>	2004	23.3402	2010	2012	
8	<a href="#">Bujko K, 2006, BRIT J SURG, V93, P1215, DOI</a>	2006	29.0577	2010	2014	
9	<a href="#">Gunderson LL, 2004, J CLIN ONCOL, V22, P1785, DOI</a>	2004	6.4487	2010	2012	
10	<a href="#">Pahlman L, 2007, BRIT J SURG, V94, P1285, DOI</a>	2007	8.6042	2010	2012	
11	<a href="#">Nagtegaal ID, 2005, J CLIN ONCOL, V23, P9257, DOI</a>	2005	7.3106	2010	2012	
12	<a href="#">Mohiuddin M, 2006, J CLIN ONCOL, V24, P650, DOI</a>	2006	15.5216	2010	2012	
13	<a href="#">Gerard JP, 2006, J CLIN ONCOL, V24, P4620, DOI</a>	2006	62.5156	2010	2014	
14	<a href="#">Sauer R, 2004, NEW ENGL J MED, V351, P1731, DOI</a>	2004	157.2532	2010	2012	
15	<a href="#">Marijnen CAM, 2005, J CLIN ONCOL, V23, P1847, DOI</a>	2005	15.2448	2010	2013	
16	<a href="#">Stipa F, 2006, ANN SURG ONCOL, V13, P1047, DOI</a>	2006	10.6361	2010	2011	
17	<a href="#">Bosset JF, 2005, J CLIN ONCOL, V23, P5620, DOI</a>	2005	18.5576	2010	2011	

	<a href="#">DOI</a>	5			2	
	<a href="#">Folkesson J, 2005, J CLIN ONCOL, V23, P5644, DOI</a>	200	18.8787	<b>2010</b>	201	
18	<a href="#">DOI</a>	5			3	
	<a href="#">Bujko K, 2004, RADIOTHER ONCOL, V72, P15, DOI</a>	200	13.0624	<b>2010</b>	201	
19	<a href="#">DOI</a>	4			1	
	<a href="#">Bosset JF, 2006, NEW ENGL J MED, V355, P1114, DOI</a>	200	88.9866	<b>2010</b>	201	
20	<a href="#">DOI</a>	6			4	
	<a href="#">Rodel C, 2007, J CLIN ONCOL, V25, P110, DOI</a>	200	13.3567	<b>2010</b>	201	
21	<a href="#">DOI</a>	7			2	
	<a href="#">Rodel C, 2005, J CLIN ONCOL, V23, P8688, DOI</a>	200	40.5083	<b>2010</b>	201	
22	<a href="#">DOI</a>	5			2	
	<a href="#">Garcia-Aguilar J, 2003, DIS COLON RECTUM, V46, P298, DOI</a>	200	13.548	<b>2010</b>	201	
23	<a href="#">DOI</a>	3			1	
	<a href="#">Peeters KCMJ, 2007, ANN SURG, V246, P693, DOI</a>	200	29.1225	<b>2010</b>	201	
24	<a href="#">DOI</a>	7			5	
	<a href="#">Guillem JG, 2008, J CLIN ONCOL, V26, P368, DOI</a>	200	12.5768	<b>2010</b>	201	
25	<a href="#">DOI</a>	8			1	
	<a href="#">Collette L, 2007, J CLIN ONCOL, V25, P4379, DOI</a>	200	14.1328	<b>2010</b>	201	
26	<a href="#">DOI</a>	7			5	
	<a href="#">Capirci C, 2008, INT J RADIAT ONCOL, V72, P99, DOI</a>	200	8.936	<b>2011</b>	201	
27	<a href="#">DOI</a>	8			2	
	<a href="#">Das P, 2007, CANCER-AM CANCER SOC, V109, P1750, DOI</a>	200	9.2045	<b>2011</b>	201	
28	<a href="#">DOI</a>	7			2	
	<a href="#">Borschitz T, 2008, ANN SURG ONCOL, V15, P712, DOI</a>	200	11.1089	<b>2011</b>	201	
29	<a href="#">DOI</a>	8			6	
	<a href="#">Valentini V, 2009, RADIOTHER ONCOL, V92, P148, DOI</a>	200	14.4947	<b>2011</b>	201	
30	<a href="#">DOI</a>	9			4	
	<a href="#">Barbaro B, 2009, RADIOLOGY, V250, P730, DOI</a>	200	8.413	<b>2011</b>	201	
31	<a href="#">DOI</a>	9			2	
	<a href="#">Bipat S, 2004, RADIOLOGY, V232, P773, DOI</a>	200	12.6336	<b>2011</b>	201	
32	<a href="#">DOI</a>	4			2	
	<a href="#">Willett CG, 2009, J CLIN ONCOL, V27, P3020, DOI</a>	200	9.4673	<b>2011</b>	201	
33	<a href="#">DOI</a>	9			2	
	<a href="#">Habr-Gama A, 2006, J GASTROINTEST SURG, V10, P1319, DOI</a>	200	6.9395	<b>2011</b>	201	
34	<a href="#">DOI</a>	6			3	
	<a href="#">Tulchinsky H, 2008, ANN SURG ONCOL, V15, P2661, DOI</a>	200	9.5191	<b>2011</b>	201	
35	<a href="#">DOI</a>	8			4	
	<a href="#">Chan I, 2006, J CLIN ONCOL, V24, P668, DOI</a>	200	9.9451	<b>2012</b>	201	
36	<a href="#">DOI</a>	6			4	
	<a href="#">Elferink MAG, 2010, EUR J CANCER, V46, P1421, DOI</a>	201	4.276	<b>2012</b>	201	
37	<a href="#">DOI</a>	0			3	
	<a href="#">Radu C, 2008, RADIOTHER ONCOL, V87, P343, DOI</a>	200	4.276	<b>2012</b>	201	
38	<a href="#">DOI</a>	8			3	
39	<a href="#">Birgisson H, 2007, ACTA ONCOL, V46, P504, DOI</a>	200	3.7671	<b>2012</b>	201	

	<a href="#">DOI</a>	7			3	
40	<a href="#">Fernandez-Martos C, 2010, J CLIN ONCOL, V28, P859, DOI</a>	2010	10.5655	<b>2012</b>	2015	
41	<a href="#">Roels S, 2006, INT J RADIAT ONCOL, V65, P1129, DOI</a>	2006	4.276	<b>2012</b>	2013	
42	<a href="#">Chua YJ, 2010, LANCET ONCOL, V11, P241, DOI</a>	2010	12.4182	<b>2012</b>	2014	
43	<a href="#">Hofheinz RD, 2012, LANCET ONCOL, V13, P0, DOI</a>	2012	11.2815	<b>2013</b>	2018	
44	<a href="#">Glynn-Jones R, 2012, BRIT J SURG, V99, P897, DOI</a>	2012	5.1099	<b>2013</b>	2014	
45	<a href="#">Kim SH, 2009, RADIOLOGY, V253, P116, DOI</a>	2009	7.431	<b>2013</b>	2014	
46	<a href="#">Edge SB, 2010, AJCC CANC STAGING MA, V0, P0</a>	2010	11.4143	<b>2013</b>	2015	
47	<a href="#">Kalady MF, 2009, ANN SURG, V250, P582, DOI</a>	2009	16.0927	<b>2014</b>	2017	
48	<a href="#">Sebag-Montefiore D, 2009, LANCET, V373, P811, DOI</a>	2009	9.8824	<b>2014</b>	2015	
49	<a href="#">Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI</a>	2012	12.6098	<b>2014</b>	2015	
50	<a href="#">Lezoche E, 2012, BRIT J SURG, V99, P1211, DOI</a>	2012	14.2521	<b>2014</b>	2017	
51	<a href="#">Quirke P, 2009, LANCET, V373, P821, DOI</a>	2009	4.9239	<b>2014</b>	2015	
52	<a href="#">Roh MS, 2009, J CLIN ONCOL, V27, P5124, DOI</a>	2009	12.5993	<b>2014</b>	2017	
53	<a href="#">Petersen SH, 2012, COCHRANE DB SYST REV, V0, P0, DOI</a>	2012	11.1502	<b>2014</b>	2015	
54	<a href="#">Taylor FGM, 2011, ANN SURG, V253, P711, DOI</a>	2011	5.1457	<b>2014</b>	2020	
55	<a href="#">Gerard JP, 2010, J CLIN ONCOL, V28, P1638, DOI</a>	2010	2.7251	<b>2014</b>	2015	
56	<a href="#">Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI</a>	2013	11.6366	<b>2014</b>	2015	
57	<a href="#">Garcia-Aguilar J, 2012, ANN SURG ONCOL, V19, P384, DOI</a>	2012	14.8617	<b>2014</b>	2017	
58	<a href="#">Gerard JP, 2012, J CLIN ONCOL, V30, P4558, DOI</a>	2012	15.6409	<b>2015</b>	2020	
59	<a href="#">Maas M, 2010, LANCET ONCOL, V11, P835, DOI</a>	2010	29.3195	<b>2015</b>	2018	
60	<a href="#">Smith JD, 2012, ANN SURG, V256, P965, DOI</a>	2012	18.4501	<b>2015</b>	2017	
61	<a href="#">van Gijn W, 2011, LANCET ONCOL, V12, DOI</a>	2011	17.3771	<b>2015</b>	201	



	<a href="#">P575, DOI</a>	1			7	
	<a href="#">Braendengen M, 2008, J CLIN ONCOL, V26, P3687, DOI</a>	200	4.8069	<b>2015</b>	201	
62	<a href="#">Bosset JF, 2014, LANCET ONCOL, V15, P184, DOI</a>	8			6	
	<a href="#">Bosset JF, 2014, LANCET ONCOL, V15, P184, DOI</a>	201	16.0421	<b>2015</b>	202	
63	<a href="#">DOI</a>	4			0	
	<a href="#">Habr-Gama A, 2014, INT J RADIAT ONCOL, V88, P822, DOI</a>	201	11.3649	<b>2015</b>	201	
64	<a href="#">DOI</a>	4			8	
	<a href="#">Aschele C, 2011, J CLIN ONCOL, V29, P2773, DOI</a>	201	10.9674	<b>2015</b>	201	
65	<a href="#">DOI</a>	1			7	
	<a href="#">Rodel C, 2012, LANCET ONCOL, V13, P679, DOI</a>	201	9.4655	<b>2015</b>	201	
66	<a href="#">DOI</a>	2			6	
	<a href="#">Dewdney A, 2012, J CLIN ONCOL, V30, P1620, DOI</a>	201	15.1142	<b>2015</b>	201	
67	<a href="#">DOI</a>	2			7	
	<a href="#">Pettersson D, 2010, BRIT J SURG, V97, P580, DOI</a>	201	11.6998	<b>2015</b>	201	
68	<a href="#">DOI</a>	0			6	
	<a href="#">Martin ST, 2012, BRIT J SURG, V99, P918, DOI</a>	201	11.9051	<b>2015</b>	202	
69	<a href="#">DOI</a>	2			0	
	<a href="#">Maas M, 2011, J CLIN ONCOL, V29, P4633, DOI</a>	201	14.0656	<b>2015</b>	202	
70	<a href="#">DOI</a>	1			0	
	<a href="#">Habr-Gama A, 2010, DIS COLON RECTUM, V53, P1692, DOI</a>	201	9.5647	<b>2016</b>	201	
71	<a href="#">DOI</a>	0			7	
	<a href="#">Ngan SY, 2012, J CLIN ONCOL, V30, P3827, DOI</a>	201	6.6871	<b>2016</b>	201	
72	<a href="#">DOI</a>	2			7	
	<a href="#">Fokas E, 2014, J CLIN ONCOL, V32, P1554, DOI</a>	201	10.6203	<b>2016</b>	202	
73	<a href="#">DOI</a>	4			0	
	<a href="#">Habr-Gama A, 2013, DIS COLON RECTUM, V56, P1109, DOI</a>	201	16.7323	<b>2016</b>	202	
74	<a href="#">DOI</a>	3			0	
	<a href="#">Glimelius B, 2013, ANN ONCOL, V24, P81, DOI</a>	201	17.1507	<b>2016</b>	201	
75	<a href="#">DOI</a>	3			8	
	<a href="#">Curvo-Semedo L, 2011, RADIOLOGY, V260, P734, DOI</a>	201	16.1945	<b>2016</b>	201	
76	<a href="#">DOI</a>	1			8	
	<a href="#">Hong YS, 2014, LANCET ONCOL, V15, P1245, DOI</a>	201	11.5852	<b>2016</b>	202	
77	<a href="#">DOI</a>	4			0	
	<a href="#">Rodel C, 2015, LANCET ONCOL, V16, P979, DOI</a>	201	30.3378	<b>2016</b>	202	
78	<a href="#">DOI</a>	5			0	
	<a href="#">Sloothaak DAM, 2013, BRIT J SURG, V100, P933, DOI</a>	201	15.0585	<b>2016</b>	201	
79	<a href="#">DOI</a>	3			8	
	<a href="#">OConnell MJ, 2014, J CLIN ONCOL, V32, P1927, DOI</a>	201	13.9201	<b>2016</b>	202	
80	<a href="#">DOI</a>	4			0	
	<a href="#">Garcia-Aguilar J, 2015, LANCET ONCOL, V16, P957, DOI</a>	201	17.3366	<b>2016</b>	202	
81	<a href="#">DOI</a>	5			0	
	<a href="#">Lambregts DMJ, 2011, ANN SURG ONCOL, V18, P2224, DOI</a>	201	11.0557	<b>2016</b>	201	
82	<a href="#">DOI</a>	1			7	
	<a href="#">Patel UB, 2011, J CLIN ONCOL, V29, P3753, DOI</a>	201	11.4741	<b>2016</b>	202	

	<a href="#">DOI</a>	1			0	
84	<a href="#">van der Paardt MP, 2013, RADIOLOGY, V269, P101, DOI</a>	201	15.5572	<b>2016</b>	201	
	<a href="#">Sauer R, 2012, J CLIN ONCOL, V30, P1926, DOI</a>	3			8	
85	<a href="#">Appelt AL, 2015, LANCET ONCOL, V16, P919, DOI</a>	201	20.4587	<b>2016</b>	202	
	<a href="#">Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI</a>	2			0	
86	<a href="#">van der Pas MHGM, 2013, LANCET ONCOL, V14, P210, DOI</a>	201	16.7323	<b>2016</b>	202	
	<a href="#">Glynn-Jones R, 2014, ANN ONCOL, V25, P1356, DOI</a>	5			0	
87	<a href="#">Garcia-Aguilar J, 2015, LANCET ONCOL, V16, P1537, DOI</a>	201	18.0899	<b>2016</b>	201	
	<a href="#">Stevenson ARL, 2015, JAMA-J AM MED ASSOC, V314, P1356, DOI</a>	0			8	
88	<a href="#">Renchan AG, 2016, LANCET ONCOL, V17, P174, DOI</a>	201	6.2169	<b>2017</b>	201	
	<a href="#">Schmoll HJ, 2012, ANN ONCOL, V23, P2479, DOI</a>	3			8	
89	<a href="#">Breugom AJ, 2015, ANN ONCOL, V26, P696, DOI</a>	201	14.3344	<b>2017</b>	202	
	<a href="#">Lefevre JH, 2016, J CLIN ONCOL, V34, P3773, DOI</a>	4			0	
90	<a href="#">Nilsson PJ, 2013, BMC CANCER, V13, P0, DOI</a>	201	16.6274	<b>2017</b>	202	
	<a href="#">Deng YH, 2016, J CLIN ONCOL, V34, P3300, DOI</a>	5			0	
91	<a href="#">Schrag D, 2014, J CLIN ONCOL, V32, P513, DOI</a>	201	10.7476	<b>2017</b>	201	
	<a href="#">Taylor FGM, 2014, J CLIN ONCOL, V32, P34, DOI</a>	5			8	
92	<a href="#">Emmertsen KJ, 2012, ANN SURG, V255, P922, DOI</a>	201	25.0436	<b>2017</b>	202	
	<a href="#">Glynn-Jones R, 2017, ANN ONCOL, V28, P22</a>	6			0	
93	<a href="#">Al-Sukhni E, 2012, ANN SURG ONCOL, V19, P2212, DOI</a>	201	6.8905	<b>2017</b>	201	
	<a href="#">Erlandsson J, 2017, LANCET ONCOL, V18, P336, DOI</a>	2			8	
94		201	15.9031	<b>2017</b>	202	
		5			0	
95		201	19.9409	<b>2018</b>	202	
		6			0	
96		201	15.2508	<b>2018</b>	202	
		3			0	
97		201	22.933	<b>2018</b>	202	
		6			0	
98		201	8.5532	<b>2018</b>	202	
		4			0	
99		201	18.6604	<b>2018</b>	202	
		4			0	
100		201	22.5052	<b>2018</b>	202	
		2			0	
101		201	41.8728	<b>2018</b>	202	
		7			0	
102		201	7.4453	<b>2018</b>	202	
		2			0	
103		201	24.217	<b>2018</b>	202	
		7			0	